Recent News

August 09, 2022

scPharmaceuticals Inc. Reports Second Quarter 2022 Financial Results and Provides Business Update

Read More
July 13, 2022

scPharmaceuticals Inc. to Participate in the Maxim Group LLC Late-Stage Advancements in Heart Failure Therapeutics and Management Panel Discussion

Read More
July 12, 2022

scPharmaceuticals Inc. Announces Positive Results from the AT HOME-HF Phase 2 Pilot Study in Heart Failure

Read More
June 30, 2022

scPharmaceuticals Inc. to Host FUROSCIX® (furosemide) 80mg/10mL for Subcutaneous Administration Commercial Day: An Investigational Treatment for Heart Failure Patients

Read More